However, currently, use of a third-generation EGFR TKI is limited as a primary treatment, with subsequent use restricted to patients with T790M-variant disease.11 Therefore, investigating the efficacy of treatments with excellent BBB permeability to intracranial tumors, regardless of T790M status, is important in patients with EGFR-variant NSCLC with brain metastases. Here, EGFR is linked to non-small cell lung carcinoma.